---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-306915"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:22:04.405305+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026

## Summary
- Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.
- CEO expects FDA meeting later in 2025 to discuss clinical/regulatory pathways for acute kidney injury.
- Company plans to start Phase 2/3 AKI study in 2026, building manufacturing and CRO infrastructure.
- Stockholders approved share issuance related to warrants; warrant expiration fixed to Dec 3, 2030.

## SEC filing metadata
- accession: 0001193125-25-306915
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312525306915/0001193125-25-306915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312525306915/revb-20251203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-306915
- JSON: https://secwatch.observer/filing/0001193125-25-306915.json
- Plain text: https://secwatch.observer/filing/0001193125-25-306915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.